Divi's Laboratories Limited

NSEI:DIVISLAB Stock Report

Market Cap: ₹1.5t

Divi's Laboratories Valuation

Is DIVISLAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DIVISLAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.26k
Fair Value
357.9% overvalued intrinsic discount
28
Number of Analysts

Below Fair Value: DIVISLAB (₹5757.05) is trading above our estimate of fair value (₹1257.18)

Significantly Below Fair Value: DIVISLAB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIVISLAB?

Key metric: As DIVISLAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DIVISLAB. This is calculated by dividing DIVISLAB's market cap by their current earnings.
What is DIVISLAB's PE Ratio?
PE Ratio73.9x
Earnings₹20.67b
Market Cap₹1.53t

Price to Earnings Ratio vs Peers

How does DIVISLAB's PE Ratio compare to its peers?

The above table shows the PE ratio for DIVISLAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.6x
SYNGENE Syngene International
57.1x22.0%₹286.4b
INDGN Indegene
34.6x18.0%₹132.9b
SAILIFE Sai Life Sciences
106.4xn/a₹146.8b
AKUMS Akums Drugs and Pharmaceuticals
52.4x40.0%₹78.2b
DIVISLAB Divi's Laboratories
73.9x22.0%₹1.5t

Price-To-Earnings vs Peers: DIVISLAB is expensive based on its Price-To-Earnings Ratio (73.9x) compared to the peer average (62.6x).

Price to Earnings Ratio vs Industry

How does DIVISLAB's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
DIVISLAB 73.9xIndustry Avg. 36.5xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DIVISLAB is expensive based on its Price-To-Earnings Ratio (73.9x) compared to the Asian Life Sciences industry average (36.5x).

Price to Earnings Ratio vs Fair Ratio

What is DIVISLAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIVISLAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.9x
Fair PE Ratio47.5x

Price-To-Earnings vs Fair Ratio: DIVISLAB is expensive based on its Price-To-Earnings Ratio (73.9x) compared to the estimated Fair Price-To-Earnings Ratio (47.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DIVISLAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,757.05
₹5,845.75
+1.5%
17.1%₹7,400.00₹4,118.00n/a28
Feb ’26₹5,618.55
₹5,570.85
-0.8%
18.2%₹6,983.00₹3,758.00n/a27
Jan ’26₹6,073.00
₹5,484.14
-9.7%
18.6%₹6,983.00₹3,590.00n/a28
Dec ’25₹6,172.70
₹5,484.14
-11.2%
18.6%₹6,983.00₹3,590.00n/a28
Nov ’25₹5,903.55
₹4,630.74
-21.6%
19.7%₹6,850.00₹3,000.00n/a27
Oct ’25₹5,423.80
₹4,466.81
-17.6%
16.7%₹5,740.00₹3,000.00n/a27
Sep ’25₹5,093.90
₹4,466.81
-12.3%
16.7%₹5,740.00₹3,000.00n/a27
Aug ’25₹4,917.90
₹3,951.96
-19.6%
15.0%₹4,767.00₹2,644.00n/a27
Jul ’25₹4,602.10
₹3,911.00
-15.0%
14.7%₹4,767.00₹2,643.00n/a27
Jun ’25₹4,307.20
₹3,901.64
-9.4%
14.7%₹4,767.00₹2,643.00n/a28
May ’25₹4,002.40
₹3,491.50
-12.8%
15.1%₹4,720.00₹2,541.00n/a26
Apr ’25₹3,567.95
₹3,468.92
-2.8%
15.0%₹4,720.00₹2,541.00n/a24
Mar ’25₹3,482.40
₹3,452.72
-0.9%
14.9%₹4,720.00₹2,541.00n/a25
Feb ’25₹3,655.40
₹3,400.60
-7.0%
15.9%₹4,720.00₹2,344.00₹5,618.5525
Jan ’25₹3,915.90
₹3,346.48
-14.5%
16.1%₹4,720.00₹2,344.00₹6,073.0025
Dec ’24₹3,792.70
₹3,355.27
-11.5%
15.8%₹4,720.00₹2,344.00₹6,172.7026
Nov ’24₹3,346.05
₹3,415.36
+2.1%
15.8%₹4,720.00₹2,615.00₹5,903.5525
Oct ’24₹3,765.15
₹3,427.29
-9.0%
16.1%₹4,720.00₹2,615.00₹5,423.8024
Sep ’24₹3,589.30
₹3,427.29
-4.5%
16.1%₹4,720.00₹2,615.00₹5,093.9024
Aug ’24₹3,639.50
₹3,173.96
-12.8%
15.3%₹4,720.00₹2,585.00₹4,917.9023
Jul ’24₹3,583.60
₹3,140.95
-12.4%
15.8%₹4,720.00₹2,585.00₹4,602.1022
Jun ’24₹3,525.40
₹3,122.48
-11.4%
16.0%₹4,720.00₹2,450.00₹4,307.2023
May ’24₹3,267.90
₹3,022.39
-7.5%
16.5%₹4,720.00₹2,380.00₹4,002.4023
Apr ’24₹2,823.35
₹2,998.70
+6.2%
16.9%₹4,720.00₹2,380.00₹3,567.9523
Mar ’24₹2,845.30
₹3,059.17
+7.5%
18.8%₹4,720.00₹2,380.00₹3,482.4024
Feb ’24₹3,356.85
₹3,587.54
+6.9%
14.4%₹4,720.00₹2,829.00₹3,655.4024
Analyst Price Target
Consensus Narrative from 28 Analysts
₹5.85k
Fair Value
1.5% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 09:31
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Divi's Laboratories Limited is covered by 56 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
null nullAntique Stockbroking Ltd.